LINC00472 suppresses oral squamous cell carcinoma growth by targeting miR-455-3p/ELF3 axis

Xiu Liu⁎, Xinrong Ma⁎, Hongyu Li⁎, Yu Wang⁎, Minghui Mao⁎, Chao Liang⁎,⁎, and Ying Hu⁎

⁎Beijing Institute of Dental Research, Beijing Stomatological Hospital, Capital Medical University, Beijing, China; ⁎Department of Oral and Maxillofacial & Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China; ⁎Department of Dental Implant Center, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Beijing, China

ABSTRACT
LINC00472 is reported to play a role in suppressing tumors in cancers such as lung cancer and hepatocellular carcinoma, among others. We made investigations into the effects of LINC00472 in oral squamous cell carcinoma (OSCC) progression to explore the underlying molecular mechanisms. By qRT-PCR, we assessed the LINC00472 expression in OSCC tissues and cells and performed functional analysis to investigate how LINC00472/miR-455-3p/ELF3 impacts OSCC cell proliferation, apoptosis, and cell cycle. The role that LINC00472 plays in OSCC tumor growth was examined by establishing a xenograft model. Down-regulation of LINC00472 occurred in tissues and cells of an OSCC tumor. LINC00472 overexpression caused OSCC cell proliferation to be inhibited, cell apoptosis to be promoted, and cell cycle arrest to be induced. As a competing endogenous RNA (ceRNA), LINC00472 can block miR-455-3p function and further promote ELF3 expression. The overexpression of miR-455-3p or ELF3 knockdown was shown to be capable of reversing the anti-tumor effects of LINC00472 in OSCC. In vivo experiments confirmed the tumor-suppressing role of LINC00472 in the progression of OSCC. In short, we found that the novel LINC00472 inhibits OSCC growth via the miR-455-3p/ELF3 axis. LINC00472 and its targeted miR-455-3p/ELF3 axis may represent valuable targets for treating OSCC.

1. Introduction
Oral squamous cell carcinoma (OSCC) arises from the malignant transformation of epithelial cells on the surface of the oral mucosa. In terms of oral cancers, more than 90% of the cases are OSCCs [1,2]. Smoking, drinking, and chewing areca (betel) are staple contributors to OSCCs [3–5]. Histologically, OSCC is characterized by squamous differentiation and nuclear pleomorphisms; it has a high incidence of local invasion and metastasis [6]. Surgery and radiotherapy are the primary treatments available for OSCC. The overall rate of patients with OSCC surviving for five years is about 50% [7]. The rate that stage I patients survive for five years is up to 90%, while the rate that stage IV patients survive for five years is only 10% [8]. Therefore, exploring effective early diagnostic markers and new therapeutic targets are the keys to effective OSCC treatment.

LncRNAs (over 200 nt in length) are a group of regulatory RNAs with limited protein-encoding capacity. Multiple studies have shown that IncRNAs are implicated in nearly all cell biological processes, including proliferation, differentiation, and malignant transformation [9,10]. In recent decades, many cancer types have been reported to involve the aberrant expression and dysfunction of IncRNAs, including breast cancer, ovarian cancer, lung cancer, and glioma [11–14]. Many IncRNAs were proven to have an important influence in OSCC initiation and development. For example, IncRNA PRNCR1 shows high expression in OSCC patients and causes tumor cells to proliferate and migrate by targeting the miR-326/FSCN1 axis [15]. Conversely, IncRNA MORT is down-regulated in OSCC tumor tissues and inhibits tumor malignant phenotypes by regulating ROCK1 [16]. LINC00472 is initially identified as a prognostic biomarker in breast carcinoma, and
a highly expressed LINC00472 predicts excellent disease outcomes [17]. Further studies revealed the role of LINC00472 in suppressing tumors when used to treat other tumor types [10,18–21]. However, more investigations need to be conducted to better understand the role that LINC00472 plays in terms of OSCC progression.

MicroRNAs [miRNAs] that are about 22 nt in length fall into a non-coding RNA class. They have been shown to influence post-transcriptional regulating related genes and affect multiple biological processes such as tumorigenesis and metastasis. Evidence of multiple studies can serve as proof of miRNAs playing a critical role in OSCC development. An example is differentially-expressed miR-455-3p in various tumor types.22 Han reported miR-455-3p up-regulation and promoted tumor progression in glioma patients [22]. In tumor tissues (e.g., colorectal cancer, osteosarcoma, and non-small-cell lung cancer (NSCLC)), the decrease of a tumor suppressor called miR-455-3p was traced by other scholars [23,24]. Reportedly, miR-455-3p experiences high expression in OSCC patients, and its overexpression can reverse the anti-tumor effects of X inactive specific transcript (XIST) in OSCC [25]. Meanwhile, the action mechanism of miR-455-3p in OSCC is still unclear.

In the present study, we attempted to illustrate the role and functional mechanism of LINC00472 in OSCC. The LINC00472 expression of tumor tissues and regular tissues in OSCC patients was analyzed. The role that LINC00472 plays in OSCC cell proliferation was also investigated in an overexpression experiment. The downstream miRNA/protein axis of LINC00472 was explored in terms of the relevant action mechanism. Finally, the establishment of a xenograft mouse model was completed to identify the function of LINC00472 in OSCC tumorigenesis in vivo. Based on the results of the present study, the potential of LINC00472 is highlighted as a target in treating OSCC.

2. Materials and methodology

2.1 Patient specimens

Oral squamous cell carcinoma tumor tissues and nearby normal tissues (>2 cm distal from tumor tissues) were collected from 15 patients at Beijing Stomatological Hosp., Capital Medical Univ. (June 2018 – July 2020). Chemotherapy or radiotherapy was not performed on patients ahead of surgical resection. Tumor tissues experienced immediate immersion into nitrogen liquid upon resection (~80°C storage). Experimental procedures received approval from the Human Research Ethics Board of the Stomatological Hospital of Capital Medical University (2015–92). Written informed consent was obtained from all participants.

2.2 Cell culture and transfections/lentivirus infection

American Type Culture Collection (ATCC; Manassas, Virginia, USA) was accessed to obtain OSCC cells (SCC25, SCC-9, SCC15, and CAL27) and human normal oral cell line (HOK). Cells underwent culture in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco, NY, USA), which was supplied with fetal bovine serum (10%, FBS, Gibco). The culture atmosphere and temperature were respectively 5% CO2 and 37°C.

The full length of LINC00472 experiencing cloning into a pcDNA3.1-vector was amplified using a Sangon Biotech (Shanghai, China). Then, miR-455-3p mimic/Ctrl mimic and si-ELF3/si-NC were designed and synthesized with GenePharma (Shanghai, China), and all the cell transfections were performed by a Lipofectamine 2000 (Invitrogen, CA, USA) abiding by the manufacturer’s protocols. The siRNAs sequence targeting ELF3 was si-ELF3 1#: 5’-GCUACCAUGUGGAG AAGAATT-3’ [26]. The sequence of sh-LINC00472 was as follows: 5’-GCAACAGATATGTG CAAGA-3’ [25]. For in vivo tumorigenesis experiments, lentiviral transfection was used for the establishment of a stable LINC00472-overexpressed CAL27 cell line. Lentiviruses containing the full length of LINC00472 were synthesized by Obio (Shanghai, China). Additionally, 6-well plates were used for CAL27 cell planting. After 12 h, the medium was discarded and washed with phosphate buffered saline (PBS) two times. A lentivirus-contained serum-free medium (MOI = 20) was added to the 6-well plates. After another 24-h cell culture, the lentivirus was replaced with a new medium (10% FBS). Puromycin
(Sigma-Aldrich) was added into the cell medium and cultured for 7 d to stably screen lentivirus-transfected cells.

2.3 Total RNA extraction and quantification real-time polymerase chain reaction (qRT-PCR) analyses

The lysis of OSCC tumor tissues and cells, as well as total RNA, was collected by TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). A reverse transcriptional reaction was performed to obtain complementary DNA (cDNA). The relative RNA expression was detected using real-time-PCR assay by a SYBR-Premix Ex Taq II reagent kit (Takara, Shiga, Japan). U6 was used as an internal control for miR-455-3p and GAPDH for LINC00472 and ELF3. Then, 2^ΔΔCt was used for quantified gene expression. The primers applied were GAPDH-F: 5’-GATTCCACCAGTGAGCAAATTC-3’, GAPDH-R: 5’-CTGGAAGATGGTGATGGATT-3’. U6-F: 5’-GCTTGGCACATATACTAAAAT-3’. U6-R: 5’-CGCTTCACGAATTGGCGTGTCAT-3’. LINC00472-F: 5’-CCCCAGAGACAGAGGAGCAAATT-3’; LINC00472-R: 5’-AGGTCAAGATGGGTTCGTTT-3’. miR-455-3p-F, 5’-ACACTCCAGCTGAGATGTGTCGATGGGCAT-3’, miR-455-3p-R: 5’-ACTGGTGTCGTGGAGTCGGC-3’. ELF3-F: CACTCCGGTAGCCTCATGG, ELF3-R: CAGTCGCGCGTGTCT.

2.4 CCK-8 assay

The prepared transfected SCC25 and CAL27 cells were collected and then resuspended into the DMEM medium (10% FBS) at 3 × 10^4/mL. They were then placed into a 96-well plate with 0.1 mL in each well and made to experience a culture of 0 h, 24 h, 48 h, or 72 h. Next, 10 μL CCK-8 solution (Dojindo, Tokyo, Japan) was incubated with the cells for 2 h. Finally, cell proliferation rates were quantified by measuring optical density (OD) (450 nm) values with a microplate reader (Alkali Scientific, USA).

2.5 Colony formation assay

The prepared transfected SCC25 and CAL27 cells were collected, and they were added to a 6-well plate (1000 cells for each well). The cells experienced a normal culture of about 14 d until colonies were visible. With crystal violet solution (0.1%), staining was conducted on cell colonies which were photographed with a camera, then the cell colony number was manually counted.

2.6 5-ethynyl-2'-deoxyuridine (EdU) assay

The prepared transfected SCC25 and CAL27 cells collected experienced resuspension in the DMEM medium (10% FBS, 5 × 10^5). Then, 12-well plates with 0.1 mL in each well were used for containing cells that then experienced culture for 12 h. Then, 10 μm EdU underwent incubation with the cells for 2 h (37°C) for uptake. In 4% paraformaldehyde, cells were fixed for 15 min and then underwent staining for 15 min with a ClickIT EdU Assay kit (Invitrogen; Thermo Fisher Scientific, Inc.). After cell nuclei staining was performed, an analysis was conducted on EdU-positive cells with flow cytometry (FACScan; BD Biosciences, USA).

2.7 Flow cytometry analysis for cell apoptosis and cell cycle

The prepared transfected SCC25/CAL27 cells collected underwent cold phosphate buffered saline (PBS) twice. Then in a binding buffer, the cells experienced resuspension. Then, 5 μL FITC-Annexin V (BD Biosciences, USA) along with 5 μL propidium iodide (PI, BD Biosciences) were sequentially placed into cells which were incubated for 20 min in darkness. Flow cytometry (FACScan; BD Biosciences) was used to analyze apoptosis.

For cell cycle analysis, the prepared transfected SCC25 and CAL27 cells were collected and incubated with 70% ethanol at 4°C overnight for fixation. After undergoing PBS wash twice, the cells underwent incubation with 100 μg/mL RNase-A along with 50 μg/mL PI (1 h, 37°C). The each-cell-cycle-phase percentage of cells was measured with flow cytometry (FACScan; BD Biosciences).

2.8 Dual-luciferase reporter gene experiment

To prove the direct LINC00472/3’ UTR of ELF3-and-miR-455-3p interaction, the CAL27 cells underwent a dual-luciferase reporter gene experiment. The
sequence of LINC00472 or 3’-UTR of ELF3 containing a wild type (WT) binding site of miR-455-3p experienced cloning into a pGL3 basic vector (Promega, Madison, WI, USA). Similarly, LINC00472 or 3’ UTR of the ELF3 transcript containing the mutant (MUT) binding site of miR-455-3p was cloned into a pGL3 basic vector (Promega). After 6-well-plate planting (6 × 10^5 cells a well), CAL27 cells were cultured for at least 12 h. Then, the WT or MUT reported plasmid and miR-455-3p mimic or Ctrl mimic were co-transfected into CAL27 cells. Finally, 24 h later, the activity of firefly and Renilla luciferase in every incubated group underwent measuring with a Dual-Luciferase®-Reporter-Assay System (Promega).

2.9 In vivo tumorigenesis experiment

The team has received animal experiment protocol approval from the Animal Care Committee of Beijing Stomatological Hosp., Capital Medical Univ., as well as Institutional Animal Care and Use Committee, Beijing Stomatological Hosp. (Approval No. KQYY-201611-001). Under conditions free of a specific pathogen (SPF), 10 BALB/c nude mice (male, five weeks old) were raised. The CAL27 cells were transfected with LINC00472 overexpression lentivirus for 48 h and collected in PBS with 20% FBS. The mice received an injection of these cells into the flanks. The team measured tumor length/width day about and calculated tumor volume as length × width^2 × 1/2. After 28 d, the experiments were ceased and tumors were exercised, weighed, and photographed.

2.10 Immunohistochemistry analysis

The blocks mouse subcutaneous tumors were analyzed (formalin fixation, paraffin embedment). Tissue sections (5 µm) underwent xylene deparaffinization and ethanol rehydration. Antigen retrieval was conducted for 30 min by citrate buffer boiling (pH 6.0, 10 mM). After the inhibition of endogenous peroxidase activity (10 min, 0.3% H₂O₂), sections experienced blocking in 2% serum in PBS (30 min) and ELF3-antibody incubation (1:100, ab97310, abcam; 4°C, overnight). Then, with an Envision System (Dako), they underwent secondary antibody incubation and visualization, as well as hematoxylin counterstaining. The protein semiquantitative expression was determined by the integrated option density (IOD) of ELF3. Deconvolution and downstream analysis were conducted by Free ImageJ (version 1.2; WS Rasband, National Institute of Health, Bethesda, MD) [27].

2.11 Statistical analysis

Statistical analyses were conducted on SPSS 20.0 (Statistical Product and Service Solutions; Chicago, IL). Graphs were drawn with SigmaPlot12.3 (Systat Software, San Jose, CA) along with GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA). Under the current conditions, Student’s t-test and one-way analysis of variance (ANOVA) were applied together with rank-sum test with flexibility, where P < 0.05 was of obvious value by statistics.

3. Results

Here, we aimed to explored the role of LINC00472 in OSCC. We conducted a series of in vitro and in vivo assays, and found that long noncoding RNA LINC00472 is lowly expressed in OSCC tissues and cells and LINC00472 inhibits OSCC growth via the miR-455-3p/ELF3 axis. Therefore, our data for the first investigated the functional and clinical roles of LINC00472 in OSCC, providing new insights into the pathogenesis of OSCC.

3.1 Expression of LINC00472 decreases in OSCC

Several studies have demonstrated LINC00472 as a tumor suppressor (for instance lung cancer, osteosarcoma, and hepatocellular carcinoma). The present study is the first to explore the pathological expression of LINC00472 in the tumor tissue and nearby ordinary tissues of OSCC patients. The qRT-PCR results (Figure 1a) showed more marked LINC00472 down-regulation in OSCC tumor tissues (n = 15) than that in ordinary tissues nearby (n = 15). Next, the qRT-PCR was used to compare the expression of LINC00472 in OSCC cells (SCC25, SCC-9, SCC15, and CAL27) together with the human
normal oral cell line (HOK). The LINC00472 expression underwent a more significant decrease in OSCC cell lines than HOK cells (Figure 1b). These data suggest that LINC00472 has expression down-regulation in OSCC tumor tissues/cells, implying an important function of this lncRNA in tumor progression.

### 3.2 LINC00472 Overexpression inhibited OSCC cells from proliferating

With gene expression analysis revealing the LINC00472 expression decrease in OSCC, we next sought to determine the effects of LINC00472 overexpression on the biological properties of SCC25 and CAL27 cells, which showed relatively lower LINC00472 expression in OSCC cells. By a qRT-PCR assay, the plasmid transfection efficiency of the LINC00472 overexpression group was detected. From Figure 2a, LINC00472 increased more significantly in the Ov-LINC00472 group than the negative control, which satisfies requirements for further functional analysis. Figure 2b-d demonstrates that the detected cell proliferation (with CCK-8 assay, colony formation assay, and EdU assay) and OSCC cells’ proliferation abilities were significantly inhibited by LINC00472 overexpression ($P < 0.05$).

Flow cytometry was applied to detect the cell apoptosis percentage of the Ov-LINC00472 group and determine whether the anti-proliferation activity of LINC00472 is associated with cell apoptosis or the cell cycle. The results show a significant increase in cell apoptosis percentage by LINC00472 overexpression ($P < 0.05$, Figure 2e). Analyzing cell cycle distribution with flow cytometry led to the revelation that G1-phase -cell percentage experienced an increase upon LINC00472 overexpression in both cell lines (Figure 2f). LINC00472 overexpression is shown by these results to inhibit OSCC cells from proliferating by generating cell apoptosis/cell cycle arrest.

### 3.3 LINC00472 directly targets miR-455-3p and inhibits its expression

By a competing endogenous RNA (ceRNA) mechanism, lncRNA was shown by multiple studies to regulate gene expression. Aiming at investigating the molecular mechanism of anti-tumor activity for LINC00472 in OSCC patients, the potential miRNA targets were predicted to find that LINC00472 has a binding site for miR-455-3p (Figure 3a). Then, miR-455-3p was selected for further experimentation, as it ranked first among all potential targets and multiple explorations showed a pro-tumor function of OSCC miR-455-3p [28,29]. To confirm the regulatory role of LINC00472 on miR-455-3p, a dual-luciferase reporter assay was conducted. The
WT and MUT pGL3-LINC00472 reporter plasmids were transfected into the OSCC cells. From Figure 3b, the miR-455-3p mimic reduced luciferase activities of WT pGL3-LINC00472 reporter plasmids. This inhibitory effect disappeared when the binding sites were mutated. The expression of miR-455-3p noticeably reduced in cells overexpressing LINC00472 elevated in LINC00472-silenced cells (Figure 3c). The miR-455-3p exhibited a higher expression in OSCC tumor tissues than normal tissues nearby (Figure 3d). In summary, LINC00472 appears to function as a ceRNA and miR-455-3p expression inhibitor.

3.4 miR-455-3p targets ELF3 to inhibit its expression

As miRNAs exert their biological functions by targeting the 3′UTR of protein-encoding mRNA and inhibiting their translation, potential miR-455-3p targets were further analyzed. Figure 3e shows the predicted complementary sequence between miR-455-3p and ELF3 3′UTR. Direct interactions between miR-455-3p and ELF3 3′UTR were confirmed by performing a dual-luciferase reporter assay. The WT and MUT pGL3-ELF3 reporter plasmids were transfected into OSCC cells. From Figure 3f, the miR-455-3p mimic reduced the luciferase activities of WT pGL3-LINC00472 reporter plasmids. This inhibitory effect disappeared when the binding sites were mutated. Gene expression analysis showed that the miR-455-3p mimic significantly inhibited the mRNA expression of ELF3 (Figure 3g). The expression of ELF3 decreased more significantly in OSCC tumor tissues than that of normal tissues nearby (Figure 3h).

Next, LINC00472/miR-455-3p axis was investigated to determine its effect on ELF3 expression. As shown in Figure 3i, the gain-of-function experiments revealed that ELF3 upregulation induced by LINC00472 overexpression was attenuated by miR-455-3p. The results show the involvement of LINC00472/miR-455-3p in regulating ELF3 in OSCC cells.
3.5 Anti-tumor effects of LINC00472 associated with miR-455-3p/ELF3

Investigations were conducted by performing a rescue experiment on the role miR-455-3p/ELF3 played in the function of LINC00472. From Figure 4, OSCC cells were divided into five groups: 1) Ctrl; 2) Ov-LINC00472+ Ctrl mimics; 3) Ov-LINC00472+ mir-455-3p mimics; 4) Ov-LINC00472+ si-ELF3 Ctrl; and 5) Ov-LINC00472+ si-ELF3. Function analysis results show that LINC00472 overexpression inhibited the proliferation (Figure 4a-c) and induced apoptosis (Figure 4d) and cycle arrest (Figure 4e) of OSCC cells, while Ov-LINC00472+ mir-455-3p mimicked or Ov-LINC00472+ si-ELF3 reversed these function parameters to NC levels. The results show that miR-455-3p/ELF3 mediates the anti-tumor function of LINC00472 in OSCC.

3.6 LINC00472 inhibits tumor growth of OSCC cells in mice

To ascertain how LINC00472 influences OSCC tumor growth in vivo, a tumorigenesis model was made by subcutaneously injecting the LINC00472 transfected OSCC cell CAL27 into a mouse model. The monitoring work was done on the tumor volume at a 7-d interval, with the corresponding plotting of tumor growth curves. As shown in Figure 5a, LINC00472 exhibited a significantly slower tumor growth than NC (P < 0.05). Tumors were excised from the mice and weighed.
at the end of the experiment. As shown in Figure 5b, the tumor weight presented a more significant decrease in the LINC00472 group than the NC group (P < 0.05). Next, qRT-PCR assays were conducted for detecting LINC00472’s RNA expression (Figure 5c), miR-455-3p (Figure 5d), and ELF3 (Figure 5e, left) in tumor tissues. The results show a more significant up-regulation of LINC00472 and ELF3 expressions in the LINC00472 group than the NC group, while miR-455-3p expression decreased. The immunohistochemistry (IHC) results also show a decreased ELF3 protein expression in the LINC00472 group (Figure 5e, right). These results suggest that LINC00472 overexpression led to a decreased tumor growth of OSCC in vivo. This effect might be associated with the miR-455-3p/ELF3 axis.

4. Discussion

This study aimed to investigate the role of LINC00472 in OSCC progression, with relevant cellular and molecular mechanisms observed. In previous studies, LINC00472 was found to suppress multiple cancers. For example, LINC00472 has shown a low expression level in NSCLC, breast cancer, ovarian cancer, hepatocellular carcinoma, and osteosarcoma [10,18–21]. Survival analysis results have suggested that patients with high LINC00472 expression have longer overall survival or relapse-free survival (RFS), which implies prognostic value in LINC00472 [10,18–21]. LINC00472 appears to inhibit tumors from proliferating and migrating, as well as stopping invasion and NSCLC epithelial-mesenchymal-transition (EMT) through p53-signaling pathway mediated by KLLN.
Figure 5. LINC00472 inhibits OSCC tumor growth in mice. (a) In vivo tumorigenesis model established by subcutaneously injecting LINC00472 overexpression plasmid-transfected CAL27 cells into mice. Tumor volume was measured regularly after injection and the tumor curves were plotted accordingly. (b) Tumors excised from mice, photographed and weighed. (c) LINC00472, (d) miR-455-3p, and (e) ELF3 mRNA as detected by qRT-PCR assay. (f, g) ELF3 protein expression in OSCC tumor tissues as detected by (f) Western blot and (g) immunohistochemistry (IHC) analysis (×200; scale bar 10 μm). *P < 0.05. Data presented in the mean ± standard deviation (SD).

via microRNA-149-3p and microRNA-4270 [10]. In hepatocellular carcinoma, LINC00472 has been found to suppress tumor growth through the miR-93-5p/PDCD4 pathway [18].

Continuous OSCC cell lines have been established and have become main research tools for investigations aimed at improving understanding of the disease’s etiology and searching for effective therapy strategies. There have previously been a number of OSCC cell lines produced from tissues of patients with OSCC, such as SCC25, SCC-9, Tca83, SCC15, and CAL27. CAL27, for example, was discovered by Gioanni and his colleagues [30,31] in tumor tissue from a 56-year-old Caucasian male with poorly differentiated squamous cell carcinoma in the middle of the tongue in 1982. At the time CAL27 cell line was built, its tumorigenicity in athymic nude mice had been confirmed. The histology of the CAL27 xenografts revealed that they were well differentiated squamous cell carcinomas of variable maturities. After these cell lines were established, they (SCC25 [25,32,33], SCC-9 [34,35], Tca83 [36,37], SCC15 [33,35,38], CAL27 [25,32,34,38]) has been widely used to build OSCC models for studies in vitro and in vivo, and thus regarded as representative cell lines for OSCC studying.

Based on these cellular models, the present study is the first attempt to investigate the function of LINC00472 in OSCC. It was found that LINC00472 was down-regulated in tumor tissues from OSCC patients and in vitro tumor cell models. Additionally, the overexpression of LINC00472 inhibited OSCC cells from proliferating, thus inducing cell apoptosis, arresting the cell cycle, and impacting in vivo tumorigenesis. The obtained results show that LINC00472 has an anti-tumor effect in OSCC, which is consistent with previously published data based on other tumor types.

The function of IncRNAs is dependent on its regulatory role in gene expression, which includes the level of transcribed modification, post-transcribed modification, and regulation translated [25]. For instance, IncRNAs may block the function of miRNAs via a complementary combination between IncRNA 3’UTR and miRNA, that is to say, the ceRNA mechanism [39–42]. The IncRNA-miRNA-mRNA interactions play a critical role in
tumor progression. Many scholars found miRNAs affecting OSCC cell proliferation or metastasis through regulating downstream target genes, which has therapeutic potential. However, there is a relative lack of empirical knowledge regarding miR-455-3p in OSCC.

Based on previous literature, highly-expressed miR-455-3p was found in OSCC patients. Its overexpression has been shown to reverse XIST’s anti-tumor effects in OSCC [25,43]. Furthermore, miR-455-3p can target the tumor suppressor protein BTG2 in OSCC. Through this attempt, findings indicated that LINC00472 blocked the function of miR-455-3p in OSCC cells via a sponge mechanism. The miR-455-3p up-regulation came to light in OSCC tumor tissues, with its overexpression reversing the anti-tumor effects of LINC00472 in OSCC. To further elucidate the precise mechanism of miR-455-3p in OSCC, a prediction was made on the downstream targets of miR-455-3p. ELF3 was found to be directly regulated by miR-455-3p. The epithelial cell-specific transcription factor ELF3 is documented to suppress multiple epithelial tumors, with its oncogenic properties displayed in others [44,45]. The present study found that ELF3 was down-regulated in OSCC tumor tissues. ELF3 was also overexpressed by LINC00472, but down-regulated by miR-455-3p. Additionally, ELF3 knockdown reversed the effects of LINC00472 on OSCC cell proliferation, apoptosis, and cell cycle arrest. Therefore, LINC00472 may up-regulate ELF3 to suppress OSCC progression by sponging miR-455-3p.

Conclusions

In conclusion, LINC00472 was identified as a suppressor of OSCC tumor cell proliferation and in vivo tumor growth. The function of LINC00472 appears to be dependent on up-regulating ELF3 (a tumor suppressor) expression by blocking miR-455-3p. This knowledge of LINC00472 function and its tumor regulating mechanism highlights its potential as a target for treating OSCC.

Highlights

- The long noncoding RNA LINC00472 is lowly expressed in OSCC tissues and cells
- LINC00472 inhibits the growth of OSCC in vivo and in vitro
- LINC00472 acts as a competing endogenous RNA (ceRNA) via the miR-455-3p/ELF3 axis

Acknowledgements

This work was supported by the Beijing Natural Science Foundation (Grant #7162075) and the National Natural Science Foundation of China (Grant #81570958, Grant #82071103).

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was supported by the Beijing Natural Science Foundation [7162075]; National Natural Science Foundation of China [82071103]; National Natural Science Foundation of China [81570958].

Author contributions

Ying Hu and Chao Liang designed and initiated the study. Xiu Liu, Xinrong Ma, Hongyu Li, and Yu Wang performed all assays and analyzed the data. Minghui Mao contributed the clinical data and samples. Xiu Liu, Chao Liang, and Ying Hu drafted and revised the manuscript. All authors read and approved the final manuscript.

References

[1] Islam MA, Rice J, Reesor E, et al. Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials. 2021;266:120431.
[2] Mendez E, Houck JR, Doody DR, et al. A genetic expression profile associated with oral cancer identifies a group of patients at high risk of poor survival. Clin Cancer Res. 2009;15(4):1353–1361.
[3] Ernani V, Saba NF. Oral cavity cancer: risk factors, pathology, and management. Oncology. 2015;89(4):187–195.
[4] Lu HH, Kao SY, Liu TY, et al. Areca nut extract induced oxidative stress and upregulated hypoxia inducing factor leading to autophagy in oral cancer cells. Autophagy. 2010;6(6):725–737.
[5] Morse DE, Psoter WJ, Cleveland D, et al. Smoking and drinking in relation to oral cancer and oral epithelial dysplasia. Cancer Causes Control. 2007;18(9):919–929.
[6] Sasahira T, Kirita T, Kuniyasu H. Update of molecular pathobiology in oral cancer: a review. Int J Clin Oncol. 2014;19(3):431–436.

[7] Tralongo V, Rodolico V, Luciani A, et al. Prognostic factors in oral squamous cell carcinoma. A review of the literature. Anticancer Res. 1999;19(4C):3503–3510.

[8] Sasahira T, Kirita T. Hallmarks of cancer-related newly prognostic factors of oral squamous cell Carcinoma. Int J Mol Sci. 2018;19(8):2413.

[9] Zhang S, Cao R, Li Q, et al. Comprehensive analysis of lncRNA-associated competing endogenous RNA network in tongue squamous cell carcinoma. PeerJ. 2019;7:e6397.

[10] Zou A, Liu X, Mai Z, et al. LINC00472 acts as a tumor suppressor in NSCLC through KLLN-Mediated p53-Signaling pathway via MicroRNA-149-3p and MicroRNA-4270. Mol Ther Nucleic Acids. 2019;17:563–577.

[11] Feng W, Li L, Xu X, et al. Up-regulation of the long non-coding RNA RMRP contributes to glioma progression and promotes glioma cell proliferation and invasion. Arch Med Sci. 2017;13(6):1315–1321.

[12] Gutschner T, Hämmerle M, Eissmann M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180–1189.

[13] Liu Z, Li M, Hua Q, et al. Identification of an eight-lncRNA prognostic model for breast cancer using WGCNA network analysis and a Cox-proportional hazards model based on L1-penalized estimation. Int J Mol Med. 2019;44(4):1333–1343.

[14] Xu C, Zhai J, Fu Y. LncRNA CDKN2B-AS1 promotes the progression of ovarian cancer by miR-143-3p/SMAD3 axis and predicts a poor prognosis. Neoplasma. 2020;67(4):782–793.

[15] Liu DK, Li YJ, Tian B, et al. LncRNA PRNCR1 aggravates the malignancy of oral squamous cell carcinoma by regulating miR-326/FSCN1 axis. Eur Rev Med Pharmacol Sci. 2021;25(8):3226–3234.

[16] Jin Z, Jiang S, Jian S, et al. Long non-coding RNA MRT overexpression inhibits cancer cell proliferation in oral squamous cell carcinoma by downregulating ROCK1. J Cell Biochem. 2019;120(7):11702–11707.

[17] Shen Y, Wang Z, Loo LW, et al. LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer. Breast Cancer Res Treat. 2015;154(3):473–482.

[18] Chen C, Zheng Q, Kang W, et al. Long non-coding RNA LINC00472 suppresses hepatocellular carcinoma cell proliferation, migration and invasion through miR-93-5p/PDCD4 pathway. Clin Res Hepatol Gastroenterol. 2019;43(4):436–445.

[19] Deng X, Xiong W, Jiang X, et al. LncRNA LINC00472 regulates cell stiffness and inhibits the migration and invasion of lung adenocarcinoma by binding to YBX1. Cell Death Dis. 2020;11(11):945.

[20] Fu Y, Biglia N, Wang Z, et al. Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer. Gynecol Oncol. 2016;143(3):642–649.

[21] Zhang J, Zhang J, Zhang D, et al. Down-regulation of LINC00472 promotes osteosarcoma tumorigenesis by reducing FOXO1 expressions via miR-300. Cancer Cell Int. 2020;20(1):100.

[22] Han JZ, Xiong Y, Deng HJ, et al. MiR-455-3p regulates glioma cell proliferation by targeting PAX6. Tropical J Pharmaceutical Res Tropical J Pharmaceutical Res. 2019;18(4):689–695.

[23] Sun Y, Wang Y, Yang H, et al. miR-455-3p functions as a tumor suppressor in colorectal cancer and inhibits cell proliferation by targeting TPT1. Int J Clin Exp Pathol. 2018;11(5):2522–2529.

[24] Yi X, Wang Y, Xu S. MiR-455-3p downregulation facilitates cell proliferation and invasion and predicts poor prognosis of osteosarcoma. J Orthop Surg Res. 2020;15(1):454.

[25] Wang Y, Zuo M, Jin H, et al. Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer. J Recept Signal Transduct Res. 2021;41(3):304–311.

[26] Xing L, Xue Y, Yang Y, et al. TMT-based quantitative proteomic analysis identification of integrin alpha 3 and integrin alpha 5 as novel biomarkers in pathogenesis of acute aortic dissection. Biomed Res Int. 2020;2020:1068402.

[27] Cheng CM, Shiah SG, Huang CC, et al. Up-regulation of miR-455-5p by the TGF-β-SMAD signaling axis promotes the proliferation of oral squamous cancer cells by targeting UBE2B. J Pathol. 2016;240(1):38–49.

[28] Wu J, Li Y, Liu J, et al. Down-regulation of lncRNA HCG11 promotes cell proliferation of oral squamous cell carcinoma through sponging miR-455-5p. J Gene Med. 2021;23(3):e3293.

[29] Gao X, Zhao H, Diao C, et al. miR-455-3p serves as prognostic factor and regulates the proliferation and migration of non-small cell lung cancer through targeting HOXB5. Biochem Biophys Res Commun. 2018;495(1):1074–1080.

[30] Gioannini J, Fischel JL, Lambert JC, et al. Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol. 1988;24(9):1445–1455.

[31] Wang W, Tan J. Co-inhibition of BET proteins and PD-L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD-L1 expressions. J Oral Pathol Med. 2019;48(9):817–825.

[32] Wang Y, Guo W, Li Z, et al. Role of the EZH2/miR-200 axis in STAT3-mediated OSCC invasion. Int J Oncol. 2018;52(4):1149–1164.
Cai J, Qiao B, Gao N, et al. Oral squamous cell carcinoma-derived exosomes promote M2 subtype macrophage polarization mediated by exosome-encoded miR-29a-3p. Am J Physiol Cell Physiol. 2019;316(5):C731–C740.

He B, Lin X, Tian F, et al. MiR-133a-3p Inhibits Oral Squamous Cell Carcinoma (OSCC) Proliferation and Invasion by Suppressing COL1A1. J Cell Biochem. 2018;119(1):338–346.

Guo JY, Wang YK, Lv B, et al. miR-454 performs tumor-promoting effects in oral squamous cell carcinoma via reducing NR3C2. J Oral Pathol Med. 2020;49(4):286–293.

Miao L, Liu C, Ge J, et al. Antitumor effect of TRAIL on oral squamous cell carcinoma using magnetic nanoparticle-mediated gene expression. Cell Biochem Biophys. 2014;69(3):663–672.

Yang Y, Chen D, Liu H, et al. Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma. Cell Death Dis. 2019;10(2):41.

Jiang L, Ge W, Cui Y, et al. The regulation of long non-coding RNA 00958 (LINC00958) for oral squamous cell carcinoma (OSCC) cells death through absent in melanoma 2 (AIM2) depending on microRNA-4306 and Sirtuin1 (SIRT1) in vitro. Bioengineered. 2021;12(1):5085–5098.

Lu X, Chen L, Li Y, et al. Long non-coding RNA LINC01207 promotes cell proliferation and migration but suppresses apoptosis and autophagy in oral squamous cell carcinoma by the microRNA-1301-3p/lactate dehydrogenase isofon A axis. Bioengineered. 2021;12(1):7780–7793.

Zhan H, Tu S, Zhang F, et al. MicroRNAs and long non-coding RNAs in c-Met-regulated cancers. Front Cell Dev Biol. 2020;8:145.

Zheng ZQ, Li ZX, Zhou GQ, et al. Long Noncoding RNA FAM225A Promotes Nasopharyngeal Carcinoma tumorigenesis and metastasis by acting as ceRNA to Sponge miR-590-3p/miR-1275 and Upregulate ITGB3. Cancer Res. 2019;79(18):4612–4626.

Li Q, Sun Q, Zhu B. LncRNA XIST Inhibits the Progression of Oral Squamous cell carcinoma via Sponging miR-455-3p/BTG2 Axis. Onco Targets Ther. 2020;13:11211–11220.

Li L, He Y, He XJ, et al. Down-regulation of long noncoding RNA LINC00472 alleviates sepsis-induced acute hepatic injury by regulating miR-373-3p/TRIM8 axis. Exp Mol Pathol. 2020;117:104562.

Enfield KSS, Marshall EA, Anderson C, et al. Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma. Nat Commun. 2019;10(1):5438.

Yeung TL, Leung CS, Wong KK, et al. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget. 2017;8 (10):16951–16963.